Terazawa T, Suzuki M, Goto T, Kato R, Hayashi H, Ito A, Isikawa S, Sotobata I
First Department of Internal Medicine, Nagaya University School of Medicine, Japan.
Am Heart J. 1991 May;121(5):1437-44. doi: 10.1016/0002-8703(91)90150-g.
The electrophysiologic properties of SUN1165 and its suppressive effect on supraventricular tachycardia were assessed in 14 patients, nine with atrioventricular reentrant tachycardia (AVRT) and five with atrioventricular nodal reentrant tachycardia (AVNRT). This new agent prolonged the PR interval and QRS duration but did not alter the QT interval or the corrected QT interval. It did not alter the sinus cycle length or sinus node recovery time. The drug prolonged the AH interval, HV interval, and intraatrial conduction time but did not change the effective refractory periods of the right atrium or right ventricle. SUN1165 prevented the induction of tachycardia in six of nine patients with AVRT by a complete retrograde block of the accessory pathway and prevented AVNRT in four of five patients by a complete retrograde block of the fast atrioventricular nodal pathway as well. We conclude that SUN1165 is very effective in preventing AVRT or AVNRT. Larger studies with more patients are warranted.
在14例患者中评估了SUN1165的电生理特性及其对室上性心动过速的抑制作用,其中9例为房室折返性心动过速(AVRT),5例为房室结折返性心动过速(AVNRT)。这种新药延长了PR间期和QRS时限,但未改变QT间期或校正QT间期。它未改变窦性周期长度或窦房结恢复时间。该药延长了AH间期、HV间期和心房内传导时间,但未改变右心房或右心室的有效不应期。SUN1165通过完全逆向阻断旁路,在9例AVRT患者中的6例中预防了心动过速的诱发,并且通过完全逆向阻断快速房室结通路,在5例患者中的4例中预防了AVNRT。我们得出结论,SUN1165在预防AVRT或AVNRT方面非常有效。有必要进行更多患者参与的更大规模研究。